Neonc Technologies Reports New Long-Term Survival Case in Intranasal NEO100 Trial

Biotech investors: Neonc Technologies Holdings, a Phase 2 clinical-stage biopharmaceutical company, has released new clinical data showing strengthened signals of therapeutic benefit in its investigational CNS cancer therapy.

Reporting from the New York Stock Exchange, Jane King shares an update on NEO100, Neonc’s intranasal therapy being evaluated in recurrent astrocytoma patients through Phase 1/2A trials and compassionate use programs.

🧬 Key Clinical Update

Since the company’s last announcement (8-K filed November 12), another patient has achieved:

Durable long-term survival

Radiographic remission

This new responder further reinforces the encouraging clinical activity seen in the trial.

📈 Expanded Cohort Strengthens the Signal

The clinical dataset now includes 25 patients

Findings show reproducibility and durability of therapeutic benefit

No significant toxicity has been observed to date

🔍 Why This Matters

Recurrent astrocytoma remains a difficult-to-treat central nervous system cancer with limited effective options. The growing body of evidence around intranasal NEO100 positions Neonc Technologies as an emerging innovator in CNS oncology therapeutic development.

#NeonTechnologies
#NEO100
#CNSCancer
#Astrocytoma
#BiotechStocks
#ClinicalTrials
#CancerResearch
#OncologyInnovation
#DrugDevelopment
#NASDAQ
#NewsOut
#JaneKing
#Biopharma
#CancerTreatment